The company met our estimates on revenue front and outperformed on gross/operating/net profitability in Q1FY25 on the back of stronger than anticipated growths in the US and PSAI while India came in line with expectations.The company has acquired global consumer healthcare product associated with Nicotine Replacement Therapy (NRT) from Haleon PLC for GBP 500 Mn, in line with its stated strategy to invest in growth areas such as novel molecules, digital therapeutics, and consumer healthcare including OTC and wellness products.